Anti-ZEBOV Glycoprotein Reference Antibody (Maftivimab, RUO) (VK623056)

Name: Anti-ZEBOV Glycoprotein Reference Antibody (Maftivimab, RUO)
Brand: abinScience
SKU: VK623056
Price: 176 USD
Availability: InStock

데이터시트 제품 공유 정보 복사

가격(USD):

사양:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

수량:

문의하기

개요
이미지
참고 문헌
데이터시트
SDS

개요

카탈로그 번호	VK623056
종 반응성	Zaire ebolavirus (ZEBOV) (Zaire Ebola virus)
응용 분야	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
숙주 종	Human
클론성	Monoclonal
이소타입	IgG1, kappa
생물학적 활성	Maftivimab binds with high affinity to the recombinant histidine-tagged extracellular domain protein of Ebola virus Makona strain glycoprotein (K d = 2.97 × 10 nM [1]). Maftivimab potently neutralizes Ebola pseudovirus particles in vitro, with an IC 50 of 0.17 nM [1].
타겟	Envelope glycoprotein, GP, GP1, GP1,2, GP1,2-delta, GP2, Shed GP
내독소 수준	< 10 EU/mg
순도	>95% as determined by SDS-PAGE.
정제	Protein A/G purified from cell culture supernatant.
등록번호	Q05320
형태	Liquid
저장 완충액	0.01M PBS pH 7.4. 데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요.
안정성 및 저장	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
대체 이름	REGN-3470-3471-3479, REGN-3470/REGN-3471/REGN-3479, INMAZEB™(odesivimab-ebgn, maftivimab, andatoltivimab), 2135632-36-7
배경	Envelope glycoprotein (GP) is a ~74 kDa protein. Trimeric GP1,2 complexes form the virion surface spikes and mediate the viral entry processes, with GP1 acting as the receptor-binding subunit and GP2 as the membrane fusion subunit. At later times of infection, down-regulates the expression of various host cell surface molecules that are essential for immune surveillance and cell adhesion. Down-modulates several integrins including ITGA1, ITGA2, ITGA3, ITGA4, ITGA5, ITGA6, ITGAV and ITGB1. This decrease in cell adhesion molecules may lead to cell detachment, contributing to the disruption of blood vessel integrity and hemorrhages developed during infection (cytotoxicity) (Probable). Interacts with host TLR4 and thereby stimulates the differentiation and activation of monocytes leading to bystander death of T-lymphocytes. 1. Simmons, G. et al. (2002) Journal of virology 76, 2518-28. PMID: 11836430 2. Takada, A. et al. (2000) Virology 278, 20-6. PMID: 11112476 3. Iampietro, M. et al. (2017) PLoS pathogens 13, e1006397. PMID: 28542576 4. Edri, A. et al. (2018) Frontiers in immunology 9, 1428. PMID: 30013549 5. Vande Burgt, NH. et al. (2015) Viruses 7, 5587-602. PMID: 26516900 6. Brinkmann, C. et al. (2016) Journal of virology 90, 11075-11086. PMID: 27707924 7. González-Hernández, M. et al. (2018) Journal of virology 92. PMID: 29669839 8. Rizk, MG. et al. (2017) Journal of virology 91. PMID: 28878074
참고 문헌	1. Markham A. REGN-EB3: First Approval. Drugs. 2021 Jan;81(1):175-178. [VK623056] 2. Gaudinski MR, et al. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Lancet. 2019 Mar 2;393(10174):889-898. [VK623056]
참고사항	For research use only. Not suitable for clinical or therapeutic use.